Archive · 6 Jun 2025
Wockhardt's Zaynich Faces US and European Market Launch
Wockhardt, a drug company, is getting ready to launch its new antibiotic Zaynich.
They are planning to launch it in the US and Europe where it can make a lot of money.
They had a meeting with the US government in May 2025, and plan to ask for permission to sell the drug in the US soon.
They also want to sell it in Europe and India, with an expected launch in India in the second half of the current financial year.
The drug is designed to help with difficult infections, potentially helping a lot of people in India.
The company has seen some losses, but they are becoming smaller, and the amount of money they make is increasing.
Wockhardt's Zaynich targets a USD 7 billion market opportunity in the US and Europe.
The company had a pre-NDA meeting with the USFDA in May 2025.
Filing to the USFDA is slated in the second quarter of the current fiscal.
Regulatory approval is planned for Europe and emerging markets.
Zaynich is designed for gram-negative infections and expected to help 11 lakh cases in India.
- Who
- Wockhardt is the company behind Zaynich.
- What
- Wockhardt is launching Zaynich, a new antibiotic.
- When
- US launch expected in FY2026-27; India launch in the second half of the current fiscal.
- Where
- US, Europe, and India.
- Why
- To address a large market opportunity and expand revenue.
- Drug Name
- Zaynich
- Addressable Market Opportunity
- USD 7 billion
- Expected US Launch
- FY2026-27
- Expected India Launch
- Second half of current fiscal year
- FY25 Revenue
- ₹3,012 crore
- FY25 Net Loss
- ₹57 crore